PharmaEngine, Inc. announced ONIVYDE obtains TFDA approval for new regimen in first-line treatment of metastatic PDAC. ONIVYDE in combination with fluorouracil and leucovorin for the treatment of adult patients with metastatic pancreatic adenocarcinoma. ONIVYDE in combination with oxaliplatin, fluorouracil, and leucovorin, for the first-line treatment of adult patients with metastatic pancreatic adenocarcinoma obtained approval of supplemental new drug application from Taiwan?s Food and Drug Administration (TFDA).

Phase 3 clinical trial was fully funded by Ipsen S.A.